Netflix's Competitive Moat and AI in CROs with Luis Sanchez – The Special Situations Report Episode #24

Episode Summary

Executive Summary: Luis Sanchez of LVS Advisory explains his two-strategy approach: a low-volatility event-driven portfolio built around merger arbitrage and related special situations, and a separate growth portfolio focused on quality businesses and long-term compounding. He details how qualitative scuttlebutt, contract analysis, and capital discipline drive his process, using Netflix and MedPace/Icon as case studies in what works and what can go wrong.

Main Topics: LVS Advisory’s two-strategy framework (Priority: 5/5): Luis describes the firm’s core business: an event-driven strategy for steady, uncorrelated returns and a growth strategy aimed at higher long-term compounding. Why merger arbitrage can resemble fixed income (Priority: 5/5): He argues merger arb behaves like a bond substitute because returns are spread-based, downside can be managed, and it offers low correlation to equities. Portfolio construction and learning from mistakes (Priority: 4/5): Luis explains how his growth portfolio became too optimized and concentrated, leading him to simplify rules and prioritize quality before valuation. Netflix as a culture-led growth investment (Priority: 5/5): The discussion highlights how qualitative research, ecosystem feedback, and management culture led to a bullish view on Netflix despite headline skepticism. MedPace, Icon, and the importance of business quality (Priority: 4/5): Luis contrasts MedPace’s organic model with Icon’s leveraged roll-up strategy, showing how customer feedback and culture informed his exit decisions. AI’s mixed impact on CROs and biotech (Priority: 3/5): The conversation covers how AI may both expand clinical-trial activity and pressure CRO profit pools, while uncertainty in biotech funding complicates the outlook.

Key Arguments: Merger arbitrage is a viable bond-like allocation because it has spread-based returns, downside protection, and much lower equity correlation than high-yield bonds. Modern merger contracts and legal protections have made deals harder to walk away from than the older “pennies in front of a steamroller” stereotype suggests. Successful event-driven investing depends on three filters: contract strength, shareholder approval dynamics, and regulatory risk. The event-driven strategy targets high single-digit to low-double-digit returns with minimal drawdowns and zero leverage. In growth investing, quality should come before valuation; trying to optimize both simultaneously caused mistakes. Qualitative scuttlebutt—talking to customers, employees, and industry participants—can reveal business quality that financial statements miss. Netflix was attractive not just because it became profitable, but because its culture and execution speed suggested durable competitive advantage and under-monetization via ads, sports, and games. MedPace looked compelling because of industry tailwinds, a strong culture, and superior full-service outsourcing economics, but biotech funding cyclicality broke the original thesis. Icon’s leveraged acquisition strategy created dis-synergies and customer friction, making organic growth models more appealing. AI is not necessarily a reason to avoid CROs, but it introduces new uncertainty around outsourcing, trial design, and where the profit pool will sit.

Data Points: Episode: 24 - Special Situations Report episode number LVS Advisory founded: January 2019 - Luis launched the firm with outside money in early 2019 Event-driven strategy return target: High single-digit to low-double-digit net returns - Luis’s stated objective for the event-driven portfolio Event-driven drawdown: About 5% max drawdown - Highest drawdown mentioned since inception Event-driven compounded return: Over 8% net of fees - Performance since inception Event-driven correlation: Zero correlation to major asset classes - Luis describes the strategy’s correlation profile Growth strategy launched: January 2020 - The growth portfolio began right before the COVID dislocation Growth strategy return: 60-plus percent in first year - Public return for 2020 Growth investor first-year return: Over 100% net - Some investors who entered during the dislocation Growth portfolio concentration: Top five positions >50% of portfolio - Current concentration level described Growth portfolio holdings during over-optimization period: About 20 holdings - Luis’s earlier portfolio management approach A single position in growth portfolio: 10-bagger - First 18 months of growth investing Additional big winners: Two 5-baggers - First 18 months of the growth portfolio CRO outsourcing share: Over half - Luis notes clinical trials outsourced today versus about 20% two decades ago MedPace customer scale: 500 ongoing clinical trials - Illustrating MedPace’s operating scale MedPace revenue growth: About 20% organically - Historical growth described for the company MedPace ROIC: About 60% - Luis cites very high return on invested capital MedPace stock performance since IPO: About 11x since 2016 IPO - Long-term share appreciation mentioned Biotech cycle description: Extreme capital surplus to extreme capital starvation - Luis’s characterization of the biotech funding environment 2020 merger completion rate: About 89% to 90% - Deals still mostly closed during the pandemic Netflix valuation at first purchase: About 18x on gap numbers - Luis’s estimate when he first bought Netflix Netflix initial purchase price: Below $200 - Approximate entry level for Luis’s first buys Netflix averaging range: Up into the $400s - He averaged up as conviction increased CRO industry conference booths: About 500 booths - Scope conference attended by Luis MedPace exit timing: Q1 2025 - When he took a small loss and stepped aside

Pivotal Quotes: "this is about the magic of compounding because you could look and see that as long as you can keep compounding and don't take any big losses, you're going to do quite well." — Luis Sanchez: Explaining why merger arbitrage can work as a long-term alternative to equity investing "I want to try to manufacture the best returns I can for the people who have that long time horizon and who aren't going to be sensitive to volatility." — Luis Sanchez: Describing the philosophy behind the growth strategy "Company culture is the strongest competitive advantage of any company." — Luis Sanchez: Summarizing the lens he uses to evaluate Netflix and other businesses

Implications: The episode argues that disciplined special-situations investing can offer low-correlation returns, while long-term growth success depends more on culture and business quality than on valuation models alone. Listeners should expect more emphasis on qualitative research, flexibility, and cycle awareness in volatile sectors like biotech.